Yduqs-Afya Merger Creates Brazil's Largest Education Company — But Can Diluted Shareholders Stomach the Price of Scale?
Shares of Yduqs slid 3.1% to R$10.86 on September 24 as investors digested the blockbuster merger terms announced the prior evening. Yduqs and Afya signed a binding agreement for a business combination that would create Brazil's dominant private higher-education platform — roughly 1.6 million students, combined net revenue of R$9.4 billion, and adjusted EBITDA of about R$3.6 billion . The sell-off signals that Yduqs shareholders are doing the math on dilution.
Afya's Shareholders Get the Bigger Slice of the Pie. Afya shareholders will own 69% of the combined entity, with Yduqs holders retaining just 31% on a fully diluted basis . Each Afya share converts into 6.408347 newly issued Yduqs shares , massively expanding the share count. While the companies describe this as a merger, the structure hands Afya and its shareholders — led by German media giant Bertelsmann — the greater economic and governance weight . Afya's CEO will lead the combined company, and Bertelsmann's education chief becomes chairman . For Yduqs investors, this is effectively a takeover dressed up as a merger of equals.
The Synergy Promise Is Large but Unproven. The companies project R$2.0–2.2 billion in synergies (roughly US$389–428 million), with 80% expected within three years of closing . Most savings come from cutting administrative costs and capital-expenditure overlap, though the companies haven't detailed specifics . JPMorgan set a wider range of R$1.3–2.8 billion , underscoring how uncertain the real number is. Yduqs itself has been struggling — its return on equity sits at just 5.98%, well below the peer average of 11.3%, and its debt-to-equity ratio has climbed to 172.88% .
Medical Schools Are the Crown Jewel — and the Antitrust Risk. Premium programs, including medicine and Ibmec, would supply 55% of revenue and roughly two-thirds of earnings; medical programs alone would generate about 45% of revenue . That concentration is precisely why Brazil's antitrust watchdog, CADE, must still approve the deal, assessing local-market overlap, especially in government-regulated medical-school seats . CADE has blocked an education merger before .
The Clock Is Ticking — and So Is the Uncertainty. Break-up fees escalate from R$325 million to R$650 million after shareholder approval, and closing isn't expected until March 31, 2028 . That leaves 18 months of execution risk while Yduqs shareholders hold a shrinking stake in a company someone else will run.